CRBU Stock Risk & Deep Value Analysis
Caribou Biosciences Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About CRBU Stock
We analyzed Caribou Biosciences Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran CRBU through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
CRBU Risk Analysis & Red Flags
What Could Go Wrong
Caribou Biosciences could fail to secure sufficient non-dilutive funding or additional equity financing to sustain its high cash burn, which was previously estimated at $200-220M for FY2026. This would lead to significant shareholder dilution or operational slowdowns if crucial clinical milestones for assets like CB-011 are delayed beyond their projected timelines, potentially eroding investor confidence and market value.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
Medium
Red Flags
- ⚠
High cash burn rate (estimated $200-220M for FY2026) significantly outweighs Q1 2026 revenue of $2.4M, necessitating ongoing financing.
- ⚠
Heavy reliance on successful clinical trial outcomes for its lead asset (CB-011) and broader pipeline, where any setback could be detrimental to the entire thesis.
- ⚠
Uncertainty around the terms and timing of future financing rounds, which are critical for maintaining operational runway.
Upcoming Risk Events
- 📅
Negative or inconclusive clinical trial data from CB-011 or vispa-cel during 2026-2027: Could lead to pipeline delays or discontinuation, significantly impacting valuation.
- 📅
Highly dilutive equity financing round by H2 2026 / H1 2027: Required to fund ongoing operations, could depress share price if terms are unfavorable or dilution exceeds 20%.
When to Reconsider
- 🚪
Exit if cash and cash equivalents reported in SEC filings drop below $100M, indicating a critically short cash runway (e.g., less than 6-9 months at current burn rate).
- 🚪
Sell if Phase 1/2 clinical data for CB-011 shows significantly reduced Objective Response Rate (ORR) below 70% or unmanageable safety signals in upcoming readouts.
- 🚪
Exit if the company announces a dilutive equity offering that results in a >25% increase in shares outstanding without a corresponding, material advancement of the pipeline.
Unlock CRBU Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Caribou Biosciences Inc (CRBU) Do?
Market Cap
$190.43M
Sector
Healthcare
Industry
Biotechnology
Employees
147
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Visit Caribou Biosciences Inc WebsiteInvestment Thesis
If Caribou Biosciences successfully advances CB-011 through pivotal Phase 2 trials and receives expedited regulatory approval via its RMAT designation within the next 3-5 years, then the company's valuation could re-rate from its current $0.18B to over $1.5B (potential 8x+). This re-rating will be driven by its 'off-the-shelf' allogeneic CAR-T platform addressing a multi-billion dollar oncology market with a significant competitive advantage in manufacturing and accessibility, currently underappreciated by its small market cap.
Is CRBU Stock Undervalued?
Unlock the full AI analysis for CRBU
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
CRBU Price Targets & Strategy
12-Month Target
$9.20
Bull Case
$18.40
Bear Case
$0.90
Valuation Basis
Based on a 5x re-rating of current market cap (to $0.9B) due to sustained clinical progress for CB-011, divided by approximately 98 million shares outstanding.
Entry Strategy
Dollar-cost average at current levels ($1.70 - $2.00) and on any dips, accumulating positions as further positive clinical data for CB-011 or vispa-cel emerges.
Exit Strategy
Take 50% profit if price reaches $9.00 - $10.00 within 12-18 months. Consider full exit above $18.00 if commercialization pathways are clear. Set a stop-loss order if price consistently closes below $1.50 (technical support level).
Portfolio Allocation
8-12% for aggressive risk tolerance.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is CRBU Financially Healthy?
Profitability
Operating Margin
-1257.42%
Net Margin
-1189.14%
Return on Equity
-100.13%
Revenue Growth
12.96%
EPS
$-1.42
Balance Sheet
Current Ratio
5.71
Quick Ratio
5.60
Other
Beta (Volatility)
2.42
Does CRBU Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
The moat is primarily derived from its advanced CRISPR technology and early clinical lead with CB-011's RMAT designation. Durability depends on continued successful clinical development, broad patent protection, and fending off competitors with alternative gene-editing approaches or competing allogeneic platforms.
Moat Erosion Risks
- •Patent litigation challenges from other CRISPR technology holders or gene-editing companies.
- •Development of superior or equally effective allogeneic CAR-T therapies by competitors, eroding first-mover or technological advantages.
- •Clinical failures or significant safety concerns with lead assets, undermining the platform's perceived value and differentiation.
CRBU Competitive Moat Analysis
Sign up to see competitive advantages
CRBU Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral to Bullish, driven by high-potential biotech narrative and clinical milestones.
Institutional Sentiment
Positive, evidenced by Bank of America Securities reiterating a 'Buy' rating and at least one analyst price target increase, despite some mixed adjustments.
Insider Activity (Form 4)
No specific Form 4 insider transaction details were provided in the research context for the last 90 days, so specific buys/sells or dollar values cannot be verified.
Options Flow
Normal options activity.
Earnings Intelligence
Next Earnings
Estimated early August 2026 (for Q2 2026 results)
Surprise Probability
Medium
Historical Earnings Pattern
Too early in commercialization to establish a clear historical pattern; stock reaction typically tied to pipeline updates and regulatory milestones rather than revenue figures, which are currently minimal.
Key Metrics to Watch
Competitive Position
Top Competitor
Allogene Therapeutics (ALLO)
Market Share Trend
Currently negligible market share; aiming to establish leadership in the allogeneic CAR-T space.
Valuation vs Peers
Trades at a discount on market capitalization compared to more advanced allogeneic CAR-T or CRISPR gene-editing peers (e.g., ALLO, CRSP), reflecting its earlier clinical stage and higher risk profile, but also larger potential upside percentage.
Competitive Advantages
- •Proprietary CRISPR genome-editing platform (chRDNA) enabling 'off-the-shelf' therapies.
- •FDA RMAT designation for lead candidate CB-011, accelerating regulatory pathway and market access.
- •Potential for superior safety and efficacy profile with specific gene editing strategies for CAR-T cell persistence and alloreactivity control.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive CRBU Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 earnings report (estimated early August 2026): Positive updates on clinical trial enrollment and cash runway.
- •2026 EHA Annual Meeting (announced May 12, 2026): Oral presentations for vispa-cel and CB-011 providing further data validation and visibility.
Medium-Term (6-18 months)
- •Additional Phase 1/2 clinical data readouts for CB-011 (anti-BCMA) by H1 2027: Confirmation of sustained high ORR and safety profile, driving further pipeline de-risking.
- •Initiation of a Phase 2 trial for vispa-cel (anti-CD19) by Q4 2026: Expansion of clinical pipeline and validation of platform's broader applicability.
Long-Term (18+ months)
- •Potential strategic partnership for late-stage development or commercialization of CB-011 by 2028: Significant non-dilutive funding and market access.
- •Biologics License Application (BLA) filing for CB-011 by 2029 (assuming expedited RMAT pathway): Signals proximity to market entry and substantial revenue potential (e.g., $500M+ peak sales).
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for CRBU?
- ✓
Monitor CB-011 clinical data for sustained Objective Response Rate (ORR) and Complete Response (CR) rates, particularly at 6-month follow-ups, with a target of >80% ORR to maintain thesis strength.
- ✓
Track cash burn rate and cash runway (e.g., from quarterly 10-Q filings) to ensure sufficient capital for at least 12-18 months of operations, signaling financial stability or upcoming financing needs.
- ✓
Watch for any new strategic partnerships or licensing agreements for its pipeline assets, which would validate the platform and provide non-dilutive funding.
Bull Case Analysis
Sign up free to see the bull case
Competing with CRBU
See how Caribou Biosciences Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Caribou Biosciences Inc CRBU | $190.4M | 7.2 | — | — | -1189.1% | 13.0% | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Caribou Biosciences Inc Makes Money
Caribou Biosciences is a clinical-stage biotechnology company that aims to revolutionize cancer treatment by developing gene-edited 'off-the-shelf' cell therapies. Unlike personalized autologous therapies which use a patient's own cells, Caribou's allogeneic (donor-derived) CAR-T cell therapies are designed to be readily available for immediate use, offering a more scalable, affordable, and accessible treatment option for cancer patients. The company's primary goal is to progress its lead drug candidates, like CB-011 for multiple myeloma, through clinical trials, ultimately generating revenue from therapeutic product sales and potential licensing agreements with larger pharmaceutical partners, while currently relying on equity financing to fund its extensive research and development.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Caribou Biosciences Inc (CRBU)?
As of June 9, 2026, Caribou Biosciences Inc has a DVR Score of 7.2 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Caribou Biosciences Inc?
Caribou Biosciences Inc's market capitalization is approximately $190.4M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Caribou Biosciences Inc use?
CRBU is the ticker symbol for Caribou Biosciences Inc. The company trades on the NMS.
What is the risk level for CRBU stock?
Our analysis rates Caribou Biosciences Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
Is Caribou Biosciences Inc's revenue growing?
Caribou Biosciences Inc has reported revenue growth of 13.0%. The company is showing strong top-line momentum.
Is CRBU stock profitable?
Caribou Biosciences Inc has a profit margin of -1189.1%. The company is currently unprofitable.
How often is the CRBU DVR analysis updated?
Our AI-powered analysis of Caribou Biosciences Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on June 9, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for CRBU (Caribou Biosciences Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.